Corticosteroids vs placebo compared
- Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes onlyno estimate extracted1 study · 180 participantsHigh
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in total population randomised compared with placebo compared (low certainty).
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in screened population compared with placebo compared (moderate certainty).
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
Oral corticosteroids may leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (low certainty).
Potent/very potent topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
Potent/very potent topical corticosteroids may leads to higher orofacial cleft compared with no topical corticosteroids (low certainty).
Potent/very potent topical corticosteroids may leads to higher low birth weight compared with no topical corticosteroids (low certainty).
Potent/very potent topical corticosteroids may leads to higher preterm delivery compared with no topical corticosteroids (low certainty).
Potent/very potent topical corticosteroids may leads to higher foetal death compared with no topical corticosteroids (low certainty).
Potent/very potent topical corticosteroids may leads to higher low Apgar score compared with no topical corticosteroids (low certainty).
High‐dose corticosteroids showed no clear difference in ambulation compared with moderate‐dose or no corticosteroids (low certainty).
High‐dose corticosteroids showed no clear difference in survival (long term) Over two years compared with moderate‐dose or no corticosteroids (low certainty).
High‐dose corticosteroids showed no clear difference in pain reduction compared with moderate‐dose or no corticosteroids (low certainty).
High‐dose corticosteroids showed no clear difference in urinary continence One week after treatment compared with moderate‐dose or no corticosteroids (low certainty).
The review found no eligible studies for this question.
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
The review found no eligible studies for this question.